IDE and Hypoglycemia: Our group has been exploring an alternative approach to boosting insulin signaling that obviates the risk of hypoglycemia: namely, pharmacological inhibition of insulin-degrading enzyme (IDE) [26], the principal protease implicated in the catabolism and inactivation of insulin [27].